drugset / Trial / NCT01048333

Evaluate Onset of Effect in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Formoterol Turbuhaler®

NCT01048333

Phase 2 Completed 109 enrolled AstraZeneca
RandomizedCrossoverDouble-blindTreatment

Summary

* Primary objective is to evaluate time to onset of effect of formoterol, 9 μg single dose,compared with salmeterol, 50 μg single dose, in patients with moderate COPD.Forced Expiratory Volume in 1 second (FEV1) measured by spirometry 5 minutes postdose. * Secondary efficacy variables: Average FEV1 during the first 15 minutes (area under the FEV1 curve from 0 to 15 minutes), Average FEV1 during 120 minutes (area under the FEV1 curve from 0 to 120 minutes)

Timeline

Start
2010-01
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 9 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled